Findings

What do systematic reviews say?

14 questions · 14 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 7.1%GRADE not reported 0 · 0%Very low 1 · 7.1%Low 12 · 85.7%Moderate 0 · 0%High 0 · 0%

High‐dose rhGH vs placebo

FEV1 % predicted: absolute change from baseline · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low

High‐dose rhGH vs placebo

FVC (% predicted) Change from baseline · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low

High‐dose rhGH vs placebo

Height velocity (cm/year) · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low

High‐dose rhGH vs placebo

Change in weight (kg) · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low

High‐dose rhGH vs placebo

QoL · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Very low

High‐dose rhGH vs placebo

Fasting blood glucose (mg/dL) · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low

High‐dose rhGH vs placebo

Number of pulmonary exacerbations or hospitalisations · children and young adults with CF

High‐dose rhGH showed no clear difference in number of pulmonary exacerbations or hospitalisations compared with placebo (low certainty).

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
RR 1.92 [0.66, 5.61]
1 study · 42 participants
Low

High‐dose rhGH vs standard‐dose rhGH

FEV1 % predicted: absolute change from baseline · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Low

High‐dose rhGH vs standard‐dose rhGH

FVC (% predicted) Change from baseline · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Low

High‐dose rhGH vs standard‐dose rhGH

Height velocity (cm/year) · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Low

High‐dose rhGH vs standard‐dose rhGH

Change in weight (kg) · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Low

High‐dose rhGH vs standard‐dose rhGH

QoL · children and young adults with CF

The review found no eligible studies for this question.

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐dose rhGH vs standard‐dose rhGH

Fasting blood glucose (mg/dL) · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Low

High‐dose rhGH vs standard‐dose rhGH

Number of pulmonary exacerbations or hospitalisations · children and young adults with CF

High‐dose rhGH showed no clear difference in number of pulmonary exacerbations or hospitalisations compared with standard‐dose rhGH (low certainty).

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
RR 1.28 [0.52, 3.18]
1 study · 42 participants
Low